The Anaphylaxis drugs in development market research report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anaphylaxis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Anaphylaxis by 19 companies/universities/institutes. The top development phase for Anaphylaxis is phase i with eight drugs in that stage. The Anaphylaxis pipeline has 18 drugs in development by companies and two by universities/ institutes. Some of the companies in the Anaphylaxis pipeline products market are: Pasteur Institute, Aquestive Therapeutics and Crossject.
The key targets in the Anaphylaxis pipeline products market include Beta Adrenergic Receptor, Alpha Adrenergic Receptor, and Alpha 1 Adrenergic Receptor.
The key mechanisms of action in the Anaphylaxis pipeline product include Alpha Adrenergic Receptor Agonist with eight drugs in Phase III. The Anaphylaxis pipeline products include ten routes of administration with the top ROA being Nasal and three key molecule types in the Anaphylaxis pipeline products market including Small Molecule, and Monoclonal Antibody.
Anaphylaxis overview
Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways, and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma, and family history. Treatment includes beta-agonists, antihistamines, and cortisone.
For a complete picture of Anaphylaxis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
